Novavax Stock News

The vaccine developer's shares got a hefty pop on the announcement of a collaboration deal. In the mind of one pundit tracking the stock, however, this means the shares are now fairly valued, and migh

Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.

Novavax just eliminated its biggest risk thanks to a billion-dollar deal with pharma giant Sanofi. The agreement could also boost long-term growth.

NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlem

The biotech industry is notably risky, but can produce stocks that see massive gains within a day. How can this happen?

No, it's not 2021. But waking up today, you might have been forgiven for thinking so.

Meme stocks have the potential to completely change the portfolio health even with a limited exposure of 5% to 10%. The best example now is Carvana (NYSE: CVNA ), which surged from under-$5 levels at

Novavax stock more than doubled in response to a licensing deal with a big pharma partner. Sanofi will give Novavax $500 million up front to co-license and co-commercialize its COVID-19 vaccine.

GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.

Monday's market action tells us that meme stocks are back in play. However, because not all meme stocks are created equally, investors should focus on those with fundamental catalysts.

Novavax announced Q1 2024 results with a beat on EPS and a miss on revenue, causing a surge in premarket trading. Novavax finalized a licensing agreement with Sanofi worth up to $1.2B, boosting its CO

Novavax, Inc. (NASDAQ:NVAX ) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Execu

Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Televi